----
Current ValuationThe current P/E ratio is 13.83, within the reasonable range, cheaper than 55.33% of the time in the past 5 years, and the industry ranks 22/255, the industry Median -1.27.
13.83xP/E
$25.54Stock price
$1.85Earnings per share
13.83xP/E
Stock price$25.54Earnings per share$1.85
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 14.86x
- Typical range
- 10.52x–20.61x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0285684112
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
BMYUSBristol Myers Squibb | 13.14x | 62.25% | $121.95B |
GSKUSGSK | 14.87x | 16.02% | $95.81B |
UCBJYUSUCB S.A. | 17.10x | -- | $43.55B |
HLNUSHaleon | 18.31x | 1.74% | $39.73B |
OTSKYUSOtsuka Pharmaceutical | 14.69x | -- | $38.02B |
DSNKYUSDaiichi Sankyo | 18.59x | -- | $31.22B |
ZTSUSZoetis | 11.21x | 6.76% | $29.57B |
ALPMYUSAstellas Pharma | 10.95x | -- | $25.53B |
JAZZUSJazz Pharma | 15.95x | 322.05% | $15.01B |
OPHLYUSOno Pharmaceutical | 13.69x | -- | $6.67B |
INDVUSIndivior Pharmaceuticals | 11.98x | 126.83% | $4.26B |
HYPMYUSHypera S.A. | 11.57x | -- | $3.80B |
OGNUSOrganon | 17.33x | 211.11% | $3.62B |
SNPHYUSSanten Pharmaceutical | 13.90x | -- | $3.43B |
LQDAUSLiquidia Tech | 17.23x | 410.63% | $2.39B |
HRMYUSHarmony Biosciences | 12.64x | 45.48% | $2.29B |
PBHUSPrestige Brands | 13.10x | 7.48% | $2.25B |
ANIPUSANI Pharma | 16.23x | 51.20% | $1.62B |
GTBIFUSGreen Thumb Industries Inc. | 12.18x | -- | $1.54B |
PAHCUSPhibro Animal Health | 15.36x | 26.75% | $1.53B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
